Immune-mediated inflammatory diseases (IMIDs) most often affect young patients and have high impact on morbidity and mortality with a significant alteration in the quality of life of patients with professional, social and emotional repercussions. Beyond this burden, IMIDs share many common pathophysiological mechanisms and treatments, known as "targeted therapies". Despite progress in this field, much remains to be done in clinical, therapeutic and fundamental research to address the efficacy, resistance and side-effects of treatment. These similarities between IMIDs have led the FHU IMMINeNT to propose the creation of a prospective, multidisciplinary clinical-biological database (IMMINeNT cohort), associated to a biobank, of patients with IMIDs. The main objectives of this database will be to identify new prognostic and therapeutic biomarkers in order to develop new therapeutic targets and biomarkers, to identify prognostic factors and determinants related to the activity, severity and quality of life of patients with IMIDs as well as to the response and tolerance to treatment.
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
Change of SLEDAI for lupus
Timeframe: once a year for 10 years
Change of Medsger score
Timeframe: once a year for 10 years
Change of EDSS for multiple sclerosis
Timeframe: once a year for 10 years
Change of BASDAI for psoriatic arthristis
Timeframe: once a year for 10 years
Change of Longhurst criteria for hereditary angioedema
Timeframe: once a year for 10 years
Change of number of flares for atopic dermatitis
Timeframe: once a year for 10 years
Change of number of exacerbations for severe asthma
Timeframe: once a year for 10 years
Change of 12-Item Short-Form Health Survey (SF-12) - quality of life scale
Timeframe: once a year for 10 years
number of participant with severe infectious events
Timeframe: once a year for 10 years